- Home
- AMIX vs ALLR Comparison
AMIX vs ALLR Comparison
Compare AMIX & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- ALLR
- Stock Information
- Founded
- AMIX 2014
- ALLR 2004
- Country
- AMIX United States
- ALLR United States
- Employees
- AMIX N/A
- ALLR N/A
- Industry
- AMIX
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- AMIX
- ALLR Health Care
- Exchange
- AMIX NYSE
- ALLR Nasdaq
- Market Cap
- AMIX 5.5M
- ALLR 4.0M
- IPO Year
- AMIX N/A
- ALLR N/A
- Fundamental
- Price
- AMIX $1.74
- ALLR $0.88
- Analyst Decision
- AMIX
- ALLR
- Analyst Count
- AMIX 0
- ALLR 0
- Target Price
- AMIX N/A
- ALLR N/A
- AVG Volume (30 Days)
- AMIX 41.8K
- ALLR 2.6M
- Earning Date
- AMIX 02-13-2025
- ALLR 05-13-2025
- Dividend Yield
- AMIX N/A
- ALLR N/A
- EPS Growth
- AMIX N/A
- ALLR N/A
- EPS
- AMIX N/A
- ALLR N/A
- Revenue
- AMIX N/A
- ALLR N/A
- Revenue This Year
- AMIX N/A
- ALLR N/A
- Revenue Next Year
- AMIX N/A
- ALLR N/A
- P/E Ratio
- AMIX N/A
- ALLR N/A
- Revenue Growth
- AMIX N/A
- ALLR N/A
- 52 Week Low
- AMIX $1.52
- ALLR $0.68
- 52 Week High
- AMIX $75.80
- ALLR $174.00
- Technical
- Relative Strength Index (RSI)
- AMIX 33.31
- ALLR 42.95
- Support Level
- AMIX $1.69
- ALLR $0.91
- Resistance Level
- AMIX $2.11
- ALLR $1.23
- Average True Range (ATR)
- AMIX 0.17
- ALLR 0.14
- MACD
- AMIX -0.00
- ALLR -0.01
- Stochastic Oscillator
- AMIX 30.13
- ALLR 15.31
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.